Menu
← Oncology Approval Tracker
FDA DECISION ·
Rylaze
asparaginase erwinia chrysanthemi (recombinant)-rywn · Jazz Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients aged 1 month and older with acute lymphoblastic leukemia or lymphoblastic lymphoma and hypersensitivity to E. coli-derived asparaginase. Rylaze is part of multiagent chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The recombinant product allows eligible patients to continue asparaginase therapy after hypersensitivity to another preparation.
What research teams should watch
Document the original product and reaction and recheck replacement dosing and administration dates.
PRIMARY RECORDS